A humanized yeast proteasome identifies unique binding modes of inhibitors for the immunosubunit ß5i.
EMBO J
; 35(23): 2602-2613, 2016 12 01.
Article
en En
| MEDLINE
| ID: mdl-27789522
ABSTRACT
Inhibition of the immunoproteasome subunit ß5i alleviates autoimmune diseases in preclinical studies and represents a promising new anti-inflammatory therapy. However, the lack of structural data on the human immunoproteasome still hampers drug design. Here, we systematically determined the potency of seven α' ß' epoxyketone inhibitors with varying N-caps and P3-stereochemistry for mouse/human ß5c/ß5i and found pronounced differences in their subunit and species selectivity. Using X-ray crystallography, the compounds were analyzed for their modes of binding to chimeric yeast proteasomes that incorporate key parts of human ß5c, human ß5i or mouse ß5i and the neighboring ß6 subunit. The structural data reveal exceptional conformations for the most selective human ß5i inhibitors and highlight subtle structural differences as the major reason for the observed species selectivity. Altogether, the presented results validate the humanized yeast proteasome as a powerful tool for structure-based development of ß5i inhibitors with potential clinical applications.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Complejo de la Endopetidasa Proteasomal
Límite:
Animals
/
Humans
Idioma:
En
Revista:
EMBO J
Año:
2016
Tipo del documento:
Article
País de afiliación:
Alemania